News Highlights – March 2021


March 2021 witnessed interesting developments in the landscape of precision oncology. Several companies joined forces to expand their portfolio of NGS solutions and optimize data management, including Bio-techne, Agilent and Merck, making a tender offer for the public stocks of Pandion Therapeutics.

Among this month's FDA drug approvals, Pfizer’s Lorbrena (Lornatinib) indication was extended as a first-line treatment for ALK-positive NSCLC patients, along with Ventana ALK IHC test as its CDx. In addition, Spectrum Pharmaceuticals’ poziotinib, received a fast track designation for HER2-exon-20-mutant NSCLC patients, addressing a large unmet need. Further immunotherapies received marketing approvals for breast cancer, urothelial carcinoma and renal cell cancer.

Liquid biopsy has seen a fast change in the landscape, with Guardant and FMI expanding access in different geographies and starting to redefine the testing practice.
Summary of news (with links)


Drug approvals (8)



Diagnostic approvals and market access (8)



Clinical trials (13)



Merge and acquisitions (7)



IVD reimbursement (1)



Partnerships (17)



Observational studies (3)



IPO (1)




Giovanni Dothel, PhD - - Inflection Point Biomedical Advisors

Jaume Calafell - - Inflection Point Biomedical Advisors